Expression of αVβ6 integrin is a poor prognostic indicator in HER2+ breast cancer and dual inhibition of αVβ6 and HER2 in mouse xenograft models improves therapeutic effect, compared with monotherapies (17). Here, ERBB2 is linked to breast carcinoma.